EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

This was the stock's second consecutive day of losses.

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Women are often underdiagnosed and undertreated when it comes to heart disease, particularly conditions like aortic stenosis.

Edwards Lifesciences (NYSE:EW – Get Free Report) had its price objective upped by Morgan Stanley from $70.00 to $75.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an ...